Column Group files Form 144 for common stock sales

COLUMN GROUP III-A, LP reported proposed sales of common stock via Form 144 for Tenaya Therapeutics.

Rhea-AI Filing Summary

COLUMN GROUP III-A, LP reported proposed sales of common stock via Form 144 for Tenaya Therapeutics. The filings list multiple sale dates and share amounts with proceeds for each transaction.

Examples shown include sales of 2,151,458 shares on 02/11/2026 (proceeds $1,464,712.61) and 349,212 shares on 02/24/2026 (proceeds $214,870.14). The entries are presented as individual proposed sales by the reporting holder.

Insights

Securities Compliance Analyst

Form 144 lists proposed outbound sales by a single holder with dates, share counts, and proceeds.

The filing shows multiple proposed dispositions by COLUMN GROUP III-A, LP, each with a sale date, number of common shares, and an associated proceeds figure. Examples include 02/11/2026 and 02/24/2026, with amounts shown in the excerpt.

These notices are administrative disclosures required under resale rules; actual execution and timing depend on market activity and compliance with applicable resale conditions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for TNYA show?

It shows proposed sales of Tenaya Therapeutics common stock by COLUMN GROUP III-A, LP, with dates and amounts. The excerpt lists transactions on 02/11/2026 (2,151,458 shares, $1,464,712.61) and 02/24/2026 (349,212 shares, $214,870.14).

Who is the selling party in the TNYA Form 144?

The reported selling party is COLUMN GROUP III-A, LP as shown in the excerpt. Multiple rows list that entity at a San Francisco address with individual proposed sale dates and share amounts.

How many shares are listed in the largest proposed sale in the excerpt?

The largest single row in the provided excerpt shows 2,151,458 shares on 02/11/2026 with proceeds listed as $1,464,712.61. The filing presents each sale as an individual proposed disposition.

Do these Form 144 entries confirm that the shares have been sold?

No; the entries list proposed sales and include sale dates, share counts, and proceeds figures. The excerpt presents the notices of intended sale rather than a confirmation of completed market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 05:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001668085
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tenaya Therapeutics, Inc.
SEC File Number	001-40656
Address of Issuer	171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	415-865-2066
Name of Person for Whose Account the Securities are To Be Sold	COLUMN GROUP III-A, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street, 9th floor San Francisco CA 94104	1060727	596552.86	213744535	02/25/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/30/2019	Series B financing	Tenaya Therapeutics			177927	08/30/2019	Cash
Common	12/20/2018	Series A financing	Tenaya Therapeutics			313640	12/20/2018	Cash
Common	03/30/2020	Series B financing	Tenaya Therapeutics			177927	03/30/2020	Cash
Common	08/25/2020	Series B financing	Tenaya Therapeutics			177927	08/25/2020	Cash
Common	12/17/2020	Series B financing	Tenaya Therapeutics			213306	12/17/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
COLUMN GROUP III-A, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/10/2026	182295	148770.95
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/11/2026	2151458	1464712.61
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/20/2026	277769	170800.16
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/23/2026	162291	96920.19
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/24/2026	349212	214870.14

144: Remarks and Signature

Remarks
Date of Notice	02/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Evangelista
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)